Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.23
+0.14 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
34
35
Next >
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
July 01, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SAREPTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
June 30, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Shareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class Action
June 30, 2025
From
Robbins LLP
Via
GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 30, 2025
Via
ACCESS Newswire
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
June 30, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
June 28, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
June 27, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
June 27, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
2 Beaten-Down Stocks to Avoid
↗
June 27, 2025
Via
The Motley Fool
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
June 26, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 26, 2025
From
The Schall Law Firm
Via
Business Wire
SRPT SECURITIES NOTICE: Sarepta Therapeutics, Inc. Investors May Have Been Affected by Fraud - Contact BFA Law if You Suffered Losses
June 26, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 26, 2025
Via
ACCESS Newswire
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
↗
June 25, 2025
FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.
Via
Benzinga
Topics
Death
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
↗
June 25, 2025
Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys.
Via
Investor's Business Daily
Topics
Death
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
↗
June 25, 2025
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.
Via
Stocktwits
Topics
Artificial Intelligence
Death
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
↗
June 25, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 25, 2025
Via
ACCESS Newswire
Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts
↗
June 25, 2025
Via
Benzinga
BFA Law Notifies Sarepta Therapeutics, Inc. (SRPT) Investors that the Company is being Investigated for Securities Fraud - Contact the Firm if You Lost Money
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SRPT FRAUD NOTIFICATION: Did Sarepta Therapeutics, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law
June 23, 2025
Via
ACCESS Newswire
SRPT REVIEW: Sarepta Therapeutics, Inc. is Being Investigated for Securities Fraud After Elevidys Death - Investors Are Urged to Contact BFA Law
June 20, 2025
Via
ACCESS Newswire
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
↗
June 20, 2025
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
Via
Benzinga
This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
↗
June 20, 2025
Via
Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
↗
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Via
Investor's Business Daily
Topics
Government
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
